Inclisiran (Leqvio): how it works, status and trials

Approved 2021; outcome trials ongoingsiRNA injectionLowering LDL cholesterol

Inclisiran (Leqvio) is an injection that destroys the messenger RNA liver cells use to make PCSK9, so the liver makes less of it. It is given once, again at three months, then every six months.

In technical terms: Loads into RISC and cleaves PCSK9 mRNA, so the liver makes less PCSK9.

The highlighted badge marks where Inclisiran (Leqvio) acts. Open the full map or compare every therapy.

At a glance

Acts on: PCSK9 mRNA · liver
How it is given: GalNAc-siRNA · SC day 0, month 3, then every 6 months
What the main trial found: LDL-C ≈ −50% (ORION-10/11)
Status (curated October 25, 2026): Approved 2021; outcome trials ongoing

Where it fits in the body

The LDL-receptor cycle

LDL particles are cleared from blood when they bind LDL receptors on liver cells. After the particle is taken in, a receptor normally returns to the surface and can be reused many times. PCSK9 escorts the receptor to the lysosome, where it is destroyed. Every PCSK9-pathway drug (5–10) works by keeping more receptors on the surface.

RNA and gene-editing therapies

These drugs act before a protein is made. siRNA and antisense drugs are attached to GalNAc, which hepatocytes take up, and they destroy one specific mRNA. A dose lasts weeks to months. Gene editors (10, 13) make a permanent single-dose change to the DNA and are in early trials.

See it on the interactive map

Trials and registry status

From ClinicalTrials.gov, PubMed and openFDA, refreshed monthly. Last run October 27, 2026.

Inclisiran (Leqvio) from Novartis

Stage: US approved 2021-12-22. 28 active of 53 registered trials. 13 new papers in the last 31 days.

ORION-4 (NCT03705234): active not recruiting, primary completion 2026-10
VICTORION-2P (NCT05030428): active not recruiting, primary completion 2027-05-10
NCT05739383 (NCT05739383): active not recruiting, primary completion 2029-04-16

Recent changes

October 25, 2026: PMID 42869405: Comparative Cardiovascular Outcomes Associated with Evolocumab Versus Inclisiran Among Patients with Elevated Lipoprotein(a).
October 25, 2026: PMID 42828262: Real-world treatment adherence and persistence among patients initiating inclisiran or PCSK9 mAbs.
October 25, 2026: PMID 42803952: Long-term LDL-C lowering and treatment persistence with inclisiran: 3-year follow-up from the German Inclisiran Network.
October 25, 2026: PMID 42793794: Serial Coronary Plaque Composition After Inclisiran Initiation Assessed by Automated CCTA: A Retrospective Pilot Study.
October 25, 2026: PMID 42784009: The Utilization of Inclisiran for the Optimization of Lipid Management in People Living with HIV: A Clinical Case Series and Comprehensive R

Evidence

ORION-10/11 (PubMed 32187462)

Common questions

How does Inclisiran (Leqvio) work?

Inclisiran (Leqvio) is an injection that destroys the messenger RNA liver cells use to make PCSK9, so the liver makes less of it. It is given once, again at three months, then every six months. In technical terms: Loads into RISC and cleaves PCSK9 mRNA, so the liver makes less PCSK9. It acts on PCSK9 mRNA · liver.

How much does Inclisiran (Leqvio) lower cholesterol or other lipids?

LDL-C ≈ −50% (ORION-10/11). Individual results differ, and a clinician can say what to expect for one person.

Is Inclisiran (Leqvio) approved, and what is the status?

Approved 2021; outcome trials ongoing (curated October 25, 2026). Registry stage as of October 27, 2026: Inclisiran, US approved 2021-12-22.

How is Inclisiran (Leqvio) taken?

GalNAc-siRNA · SC day 0, month 3, then every 6 months.

Leqvio Cost, Dosing, and LDL Results: Twice-a-Year Shot

Related therapies

Statins: Approved (generic)
Bempedoic acid (Nexletol, Nexlizet): Approved 2020
Ezetimibe (Zetia): Approved (generic)
Bile acid sequestrants (colesevelam): Approved (generic)

Educational, not medical advice. Mechanism and status text curated October 25, 2026; registry data refreshed October 27, 2026. Registries can lag company announcements. Effects are placebo-adjusted results from the main published trial, not head-to-head comparisons. Investigational agents are available only in clinical trials. Preval Health does not practice medicine; licensed clinicians in a partner network provide care. If you have chest pain or signs of a stroke, call 911.